CTLA4 and melanoma: Four articles including 68 patients were available of CRR of melanoma after neoadjuvant therapy, two of which combined PD‐1/PD‐L1 inhibitors and CTLA‐4 inhibitors in the neoadjuvant therapy, and the rest used PD‐1/PD‐L1 inhibitors monotherapy.